eGenesis
$38Mlatest round · Series A · Mar 2017 · 9 yr ago
5backers · Alta Partners, b2venture
50+team · employees, estimated range
26stories in the press
Overview
At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
Funding and backers
Total raised
$38M
1 round on record
Latest round
$38M
Series A · Mar 2017 · 9 yr ago
Team
51-200
employees, estimated range
Backers
5
Alta Partners, b2venture
The money's age
Long since its last round
115 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 16, 2017
Raised a round Series A $38M · led by Biomatics Capital
May 2014
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Mar 2017 | $38M | Biomatics Capital lead, ARCH Venture Partners lead | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
b2venture Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
TALKING COMPUTERS. We envision a future where humans and artificial intelligence live and work together.
We envision a future where high-quality, affordable early care and education is easily accessible for all.
A New Standard in Organ Transplantation. Accunea is pioneering the next generation of organ condition monitoring technology to ensure that…
A sustainable and profitable fashion ecosystem that is accessible to everyone. We are here to change the narrative.
About us Our Vision We envision a water and climate-resilient planet, where water and energy are accessible to all. Open Hydro aims to…
About Careers Contact Policies Scroll At Sylvatica, we're reimagining human health. We strive to transform organ transplantation, drug…
Financials
Total raised
$38M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2017 | $38M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Alta PartnersVia a fund
HBM Healthcare InvestmentsVia a fund
Khosla VenturesVia a fund
Lux CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Natco Pharma hikes investment in US-based eGenesis to $16.7 million
Under the revised structure, Natco Pharma (Canada) Inc will invest $13.70 million, while Natco Pharma USA LLC will contribute $3 million, according to a regulatory filing
Read more
Report
Natco Pharma raises eGenesis investment to $16.70 million
Natco Pharma will raise its proposed investment in US biotech firm eGenesis to $16.70 million, taking its total investment to $24.70 million.
Read more
Report
NATCO Pharma Expands Strategic Investment in eGenesis to $24.70 Million to Support Next-Generation Xenotransplantation Technology
NATCO Pharma Limited has announced an update regarding its ongoing investment in eGenesis, Inc.
Read more
Report
Natco Pharma to enhance total investment in eGenesis to $25 million
Natco Pharma raises total eGenesis investment to $24.7M via Canada and USA units, fueling pig organ transplant research and trials.
Read more
Report
Pig kidney works in human body for 271 days - is this the future of organ transplants?
A man has lived for a record nine months with a transplanted pig kidney while waiting for a human transplant.
Read more
Report
A Transplanted Pig Kidney Is Still Working After a Record-Setting 9 Months in a Patient
Gene-edited pig kidneys could offer a lifeline to patients stuck waiting for a human donor.
Read more
Report
Recipients of gene-edited pig kidneys successfully receive human organs
The pair of cases mark a milestone for the biotech company eGenesis in its wider effort to advance xenografts.
Read more
Report
eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure
CAMBRIDGE, Mass., September 03, 2026--eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure
Read more
Report
In a First, a Pig Kidney Kept a Patient Alive Until He Got a Human One . Opens in a new tab.
Read more
Report
Natco Pharma to invest $14 mn in US-based biotechnology firm eGenesis Inc
In 2024, Natco Pharma had invested $8 million in eGenesis, Inc through preferred stock
Read more
Report
Show more news